Investigation of Avacen Thermal Exchange System for Fibromyalgia Pain (AVACEN: TES)

This study has been completed.
Information provided by (Responsible Party):
Tobias Moeller-Bertram, University of California, San Diego Identifier:
First received: June 12, 2012
Last updated: July 1, 2013
Last verified: July 2013

Hypothesis: Daily use of the AVACEN Thermal Exchange System for 1 month will show improved Fibromyalgia pain and functioning markers, as assessed by biomarkers and clinical and psychological assessment. This non-invasive device is able to rapidly raise the core body temperature of the user by placing a hand in a vacuum chamber and resting it upon a heating element. The change in body temperature may change the sympathetic nervous system's activity and thereby reduce Fibromyalgia pain.

Condition Intervention Phase
Device: AVACEN Thermal Exchange System
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: AVACEN for Fibromyalgia: Altering Core Body Temperature to Relieve Pain- An Open Label Study

Resource links provided by NLM:

Further study details as provided by University of California, San Diego:

Primary Outcome Measures:
  • Improved Pain Ratings [ Time Frame: 1 month ] [ Designated as safety issue: No ]
    Lower pain ratings after 1 month treatment

Enrollment: 21
Study Start Date: June 2011
Study Completion Date: May 2013
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
Subjects with Fibromyalgia undergo twice daily use of the non-invasive device for 4 weeks.
Device: AVACEN Thermal Exchange System
Non-invasive device forms vacuum around subject's hand, enabling efficient core body temperature adjustment using heating element inside device.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Fibromyalgia diagnosis
  • Over the age of 18
  • Understands English
  • Not pregrant/planning to become pregnant
  • Average pain of 4 or greater over the last week (10 point scale)
  • Fibromyalgia pain lasting longer than 6 months

Exclusion Criteria:

  • Pregnant/Planning to become pregnant
  • Major unstable psychiatric illness
  • Major, uncontrolled systemic illness for which you may be hospitalized in the next 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01619579

United States, California
VA San Diego
La Jolla, California, United States, 92093
Sponsors and Collaborators
University of California, San Diego
  More Information

Additional Information:
No publications provided

Responsible Party: Tobias Moeller-Bertram, Associate Clinical Professor of Anesthesiology, University of California, San Diego Identifier: NCT01619579     History of Changes
Other Study ID Numbers: 110973
Study First Received: June 12, 2012
Last Updated: July 1, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by University of California, San Diego:

Additional relevant MeSH terms:
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neuromuscular Diseases
Rheumatic Diseases processed this record on June 28, 2015